Medicinal Chemistry Journal of Medicinal Chemistry
Electrophile-first screen yields covalent aminothiazole inhibitors of E2 enzyme UBE2D2
- Screening the electrophile side first gave a covalent aminothiazole hit that crystallography showed labelling two cysteines of the E2 enzyme UBE2D2, the active-site Cys85 and a second site, Cys111.
- Structure-guided changes to the amide and ester groups removed Cys111 engagement while strengthening binding at Cys85, giving a more site-selective analogue.
- That analogue blocked UBE2D2 activity in vitro and curbed A549 lung cancer cell proliferation, offering a structural starting point for selective E2 probes.
Losing Cys111 is a sensible refinement, yet E2 enzymes share a conserved active-site cysteine, so selectivity across related E2s and the wider proteome is still unproven. Without a reversible control or kinetic parameters, it is hard to tell genuine recognition of the scaffold from a warhead whose reactivity has simply been tuned.
Paper: Journal of Medicinal Chemistry ↗ Electrophile-First Screening Identifies Covalent Aminothiazole Scaffold Inhibitors for Ubiquitin-Conjugating Enzyme UBE2D2